These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36881088)

  • 1. Efficacy and Safety of Tolvaptan for Patients With Autosomal Dominant Polycystic Kidney Disease in Real-world Practice: A Single Institution Retrospective Study.
    Masuda H; Shimizu N; Sekine K; Okato A; Hou K; Suyama T; Araki K; Kojima S; Naya Y
    In Vivo; 2023; 37(2):801-805. PubMed ID: 36881088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.
    Mochizuki T; Muto S; Miyake M; Tanaka T; Wang W
    Clin Exp Nephrol; 2021 Nov; 25(11):1231-1239. PubMed ID: 34228250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
    Horie S; Muto S; Kawano H; Okada T; Shibasaki Y; Nakajima K; Ibuki T
    Clin Exp Nephrol; 2021 May; 25(5):467-478. PubMed ID: 33471240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
    Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
    J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
    Edwards ME; Chebib FT; Irazabal MV; Ofstie TG; Bungum LA; Metzger AJ; Senum SR; Hogan MC; El-Zoghby ZM; Kline TL; Harris PC; Czerwiec FS; Torres VE
    Clin J Am Soc Nephrol; 2018 Aug; 13(8):1153-1161. PubMed ID: 30026287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.
    Muto S; Okada T; Shibasaki Y; Ibuki T; Horie S
    Clin Exp Nephrol; 2021 Sep; 25(9):1003-1010. PubMed ID: 34089122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention.
    Côté G; Asselin-Thompstone L; Mac-Way F; René de Cotret P; Lacroix C; Desmeules S; Agharazii M
    Int Urol Nephrol; 2020 Feb; 52(2):343-349. PubMed ID: 32008201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.
    Moriyama T; Nakayama Y; Soejima M; Yokota Y; Ota K; Ito S; Kodama G; Nakamura N; Kurokawa Y; Yano J; Ueda U; Takamiya Y; Kaida Y; Hazama T; Shibata R; Koda Y; Fukami K
    Clin Exp Nephrol; 2021 Mar; 25(3):251-260. PubMed ID: 33141305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis.
    Lioudis M; Zhou X; Davenport E; Nunna S; Krasa HB; Oberdhan D; Fernandes AW
    BMC Nephrol; 2023 Jun; 24(1):182. PubMed ID: 37349694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
    Higashihara E; Torres VE; Chapman AB; Grantham JJ; Bae K; Watnick TJ; Horie S; Nutahara K; Ouyang J; Krasa HB; Czerwiec FS;
    Clin J Am Soc Nephrol; 2011 Oct; 6(10):2499-507. PubMed ID: 21903984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics associated with 1-year tolvaptan efficacy in autosomal dominant polycystic kidney disease with a wide range of kidney functions.
    Murakami T; Nishimura K; Ono H; Ueta S; Shibata E; Kishi S; Tamaki M; Miya K; Shima H; Tashiro M; Inoue T; Kawahara K; Nagai K; Abe H; Minakuchi J; Doi T
    J Med Invest; 2020; 67(3.4):315-320. PubMed ID: 33148908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
    Torres VE; Devuyst O; Chapman AB; Gansevoort RT; Perrone RD; Ouyang J; Blais JD; Czerwiec FS; Sergeyeva O;
    Am J Nephrol; 2017; 45(3):257-266. PubMed ID: 28166521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics May Predict Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
    Sekine A; Hoshino J; Fujimaru T; Suwabe T; Mizuno H; Kawada M; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Mandai S; Chiga M; Kikuchi H; Ando F; Mori T; Sohara E; Uchida S; Sawa N; Takaichi K; Ubara Y
    Am J Nephrol; 2020; 51(9):745-751. PubMed ID: 32784291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis.
    Li X; Li W; Li Y; Dong C; Zhu P
    Nefrologia (Engl Ed); 2023; 43(6):731-741. PubMed ID: 37150675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
    Gansevoort RT; Meijer E; Chapman AB; Czerwiec FS; Devuyst O; Grantham JJ; Higashihara E; Krasa HB; Ouyang J; Perrone RD; Torres VE;
    Nephrol Dial Transplant; 2016 Nov; 31(11):1887-1894. PubMed ID: 26681730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial.
    Muto S; Kawano H; Higashihara E; Narita I; Ubara Y; Matsuzaki T; Ouyang J; Torres VE; Horie S
    Clin Exp Nephrol; 2015 Oct; 19(5):867-77. PubMed ID: 25663351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
    Kramers BJ; van Gastel MDA; Boertien WE; Meijer E; Gansevoort RT
    Am J Kidney Dis; 2019 Mar; 73(3):354-362. PubMed ID: 30578153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
    Cornec-Le Gall E; Blais JD; Irazabal MV; Devuyst O; Gansevoort RT; Perrone RD; Chapman AB; Czerwiec FS; Ouyang J; Heyer CM; Senum SR; Le Meur Y; Torres VE; Harris PC
    Nephrol Dial Transplant; 2018 Apr; 33(4):645-652. PubMed ID: 28992127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.